Education and Training

The PMTB is grounded in several core aims: to increase active participation across specialties; to expand educational opportunities for trainees at all levels; and to promote appropriate referral of patients to clinical trials, particularly Phase I studies. The tumor board also strives to generate scholarly output, such as case-based publications or analyses arising from recurring molecular or diagnostic themes, and to continue strengthening multidisciplinary collaboration among hematology/oncology, molecular genetics, pathology, bioinformatics, biostatistics, molecular genetics, pathology, bioinformatics, biostatistics, clinical trials teams, and IT/EHR partners. Through these efforts, the PMTB advances Yale Cancer Center’s mission of embedding precision medicine into routine clinical practice.

In general, the PMTB is organized into two complementary formats: PMTB-A, focused on general clinical case discussions, and PMTB-B, designed for in-depth, didactic case analysis. Each format serves distinct educational and clinical objectives while promoting cross-specialty engagement.

At the same time, the PMTB structure remains intentionally flexible, allowing adaptation to evolving clinical needs, unusual diagnostic challenges, or novel molecular findings. This flexibility ensures that the tumor board functions not only as a clinical decision-support platform but also as a dynamic learning environment and a catalyst for innovation, fostering a collaborative culture across the cancer center.

AI in Cancer: Advancing Precision Medicine through Interdisciplinary Innovation
8 a.m. to 6 p.m. • Friday, March 20, 2026 • The Anlyan Center (TAC) Auditorium, N017

Funded by the Office of the Provost AI Initiatives, this in-person only workshop aims to catalyze new collaborations, foster the exchange of ideas, develop strategic pathways for integrating AI into cancer research and clinical care, and lay the groundwork for future externally-funded research initiatives.

The workshop is designed to highlight real-world applications of AI across the cancer care continuum, from bench to clinical implementation to population health. Equally important, the Workshop will address limitations and risks associated with AI in healthcare. Through keynotes, panels, and collaborative discussions, we will not only showcase innovation but also build the foundations of an academic and clinical ecosystem equipped to responsibly advance AI in cancer. Contacts: Meina Wang and William Oh

HSCI 9100: Molecular Genomic Pathology in Precision Medicine (alternate spring semesters)

Director: Karin Finberg, MD, PhD • 3 Credits • Wednesdays, 2 p.m. to 5 p.m.

This course provides a comprehensive exploration of the crucial roles that genomics and molecular pathology play in the field of precision medicine. This course covers a wide range of topics that are crucial for understanding the application of precision medicine for inherited, neoplastic, and infectious disease. Students will be introduced to fundamental concepts of human genomics and laboratory techniques used in molecular pathology, enabling them to analyze genetic and molecular information in clinical and research settings to advance precision medicine and personalized patient care.

Collaboration is central to Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital, enabling us to unite clinicians, scientists, data experts, and industry partners to accelerate discovery and improve patient outcomes. Our goal is to build strategic, cross-disciplinary partnerships that integrate diverse expertise, expand access to innovative technologies, and drive transformative research and clinical initiatives. Through these collaborations, we ensure that precision cancer care evolves with scientific advances and delivers tangible benefits for the patients and communities we serve.